BAY 38-7271

BAY 38-7271
	File:BAY38-7271.svg
Legal status
Legal status	In general: legal;
Identifiers
	IUPAC name (-)-(R)-3-(2-Hydroxymethylindanyl-4-oxy)phenyl-4,4,4-trifluorobutyl-1-sulfonate;
CAS Number	212188-60-8;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C20H21F3O5S
Molar mass	430.437 g/mol

BAY 38-7271 is a drug which is a cannabinoid receptor agonist developed by Bayer AG. It has analgesic and neuroprotective effects and is used in scientific research, with proposed uses in the treatment of traumatic brain injury.^[1]^[2] It is a full agonist with around the same potency as CP 55,940 in animal studies, and has fairly high affinity for both CB₁ and CB₂ receptors, with Ki values of 2.91nM at CB₁ and 4.24nM at CB₂.^[3]^[4]

Template:Pharm-stub

References

↑ Mauler F, Horváth E, De Vry J, Jäger R, Schwarz T, Sandmann S, Weinz C, Heinig R, Böttcher M. BAY 38-7271: a novel highly selective and highly potent cannabinoid receptor agonist for the treatment of traumatic brain injury. CNS Drug Reviews. 2003 Winter;9(4):343-58. PMID 14647528
↑ Mauler F, Hinz V, Augstein KH, Fassbender M, Horváth E. Neuroprotective and brain edema-reducing efficacy of the novel cannabinoid receptor agonist BAY 38-7271. Brain Research. 2003 Oct 31;989(1):99-111. PMID 14519516
↑ Mauler F, Mittendorf J, Horváth E, De Vry J. Characterization of the diarylether sulfonylester (-)-(R)-3-(2-hydroxymethylindanyl-4-oxy)phenyl-4,4,4-trifluoro-1-sulfonate (BAY 38-7271) as a potent cannabinoid receptor agonist with neuroprotective properties. Journal of Pharmacology and Experimental Therapeutics. 2002 Jul;302(1):359-68. PMID 12065738
↑ De Vry J, Rüdiger Jentzsch K. Discriminative stimulus effects of BAY 38-7271, a novel cannabinoid receptor agonist. European Journal of Pharmacology. 2002 Dec 20;457(2-3):147-52. PMID 12464360

Template:WikiDoc Sources

[1] Mauler F, Horváth E, De Vry J, Jäger R, Schwarz T, Sandmann S, Weinz C, Heinig R, Böttcher M. BAY 38-7271: a novel highly selective and highly potent cannabinoid receptor agonist for the treatment of traumatic brain injury. CNS Drug Reviews. 2003 Winter;9(4):343-58. PMID 14647528

[2] Mauler F, Hinz V, Augstein KH, Fassbender M, Horváth E. Neuroprotective and brain edema-reducing efficacy of the novel cannabinoid receptor agonist BAY 38-7271. Brain Research. 2003 Oct 31;989(1):99-111. PMID 14519516

[3] Mauler F, Mittendorf J, Horváth E, De Vry J. Characterization of the diarylether sulfonylester (-)-(R)-3-(2-hydroxymethylindanyl-4-oxy)phenyl-4,4,4-trifluoro-1-sulfonate (BAY 38-7271) as a potent cannabinoid receptor agonist with neuroprotective properties. Journal of Pharmacology and Experimental Therapeutics. 2002 Jul;302(1):359-68. PMID 12065738

[4] De Vry J, Rüdiger Jentzsch K. Discriminative stimulus effects of BAY 38-7271, a novel cannabinoid receptor agonist. European Journal of Pharmacology. 2002 Dec 20;457(2-3):147-52. PMID 12464360

[1]

[2]

[3]

[4]

Legal status
File:BAY38-7271.svg
Legal status	In general: legal
Identifiers
IUPAC name (-)-(R)-3-(2-Hydroxymethylindanyl-4-oxy)phenyl-4,4,4-trifluorobutyl-1-sulfonate
CAS Number	212188-60-8
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C₂₀H₂₁F₃O₅S
Molar mass	430.437 g/mol

BAY 38-7271

References

Navigation menu